Drug
NITD 609 clinical trials
Also written KAE609 and Cipargamin.
- studies test it
- 11
- open now
- 2
- in phase 3
- 0
- first study started
- 2012
Keep track of what changes. Save the NITD 609 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NITD 609 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)RecruitingPhase 2Novartis PharmaceuticalsNCT07811908Written as KAE609
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaRecruitingPhase 2Novartis PharmaceuticalsNCT05750628Written as KAE609 (Cipargamin)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)CompletedPhase 2Novartis PharmaceuticalsNCT07811882Written as KAE609 (Cipargamin)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)CompletedPhase 2Novartis PharmaceuticalsNCT07235033Written as KAE609
- To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaCompletedPhase 2Novartis PharmaceuticalsNCT04675931Written as Cipargamin
- Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT04321252Written as KAE609
- Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.CompletedPhase 2Novartis PharmaceuticalsNCT03334747Written as KAE609
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to MosquitosTerminatedPhase 1Novartis PharmaceuticalsNCT02543086Written as KAE609
- A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum MonoinfectionCompletedPhase 2Novartis PharmaceuticalsNCT01836458Written as KAE609
- A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infectionCompletedPhase 2Novartis PharmaceuticalsNCT01860989Written as KAE609
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infectionCompletedPhase 2Novartis PharmaceuticalsNCT01524341Written as KAE609
Codes
What other systems call NITD 609 · ClinicalTrials.gg INT005708
- MeSH (NLM) C552304NITD 609One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552304 | NITD 609 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.